Alcoholic Hepatitis in India
Get Alcoholic Hepatitis at internationally accredited (JCI/NABH) Indian hospitals at a fraction of Western costs, with end-to-end international patient support — visa, travel, stay, and follow-up care.
Alcoholic Hepatitis in UAE
Alcoholic Hepatitis at leading UAE hospitals in Dubai and Abu Dhabi — world-class care closer to home, visa-free entry for many nationalities, international specialists, and modern facilities.
Overview
Alcoholic hepatitis is a severe, acute inflammatory condition of the liver caused by heavy alcohol use, requiring prompt medical management including corticosteroid therapy, nutritional rehabilitation, and — in select cases — early liver transplantation evaluation. With a 28-day survival rate exceeding 80% in moderate-severity cases managed at high-volume hepatology centers, India and the UAE have emerged as premier international destinations for this complex care pathway. GAF Healthcare connects patients and families to JCI- and NABH-accredited liver centers in India and JCI- and DHA-accredited institutions in Dubai and Abu Dhabi, offering end-to-end medical coordination at a fraction of Western costs without compromise in clinical outcomes.
Hospital Stay: 14–28 days (initial acute-phase inpatient management; longer if severe or transplant evaluation initiated) • Total Stay in Country (Fit-to-Fly): 4–8 weeks (dependent on Maddrey Discriminant Function score at discharge, corticosteroid response, MELD score stabilization, and absence of active infection or hepatic encephalopathy) • Success Rate: 75–85% short-term survival (moderate severity, Maddrey DF < 32); 60–75% in severe disease (Maddrey DF ≥ 32) with full corticosteroid response at high-volume centers
What Is It?
Alcoholic hepatitis (AH) is an acute, immune-mediated inflammatory syndrome of the liver arising from sustained or heavy episodic alcohol consumption, histologically characterized by hepatocellular ballooning degeneration, Mallory-Denk bodies, lobular neutrophilic infiltration, and perisinusoidal fibrosis. The condition exists on a spectrum from mild, self-limiting disease to severe acute-on-chronic liver failure (ACLF), with the latter carrying a 28-day mortality of up to 30–50% without targeted therapy. Pathophysiologically, ethanol and its toxic metabolite acetaldehyde drive oxidative stress, mitochondrial dysfunction, gut dysbiosis with increased intestinal permeability, and a systemic pro-inflammatory cytokine cascade — most notably TNF-α and IL-8 — that culminates in massive hepatic necroinflammation and progressive fibrosis.
Disease severity is objectively stratified using validated scoring systems that directly guide therapy. The Maddrey Discriminant Function (DF = 4.6 × [prothrombin time – control] + total bilirubin) is the most widely used; a score ≥ 32 defines severe AH and mandates consideration of corticosteroid therapy. Complementary tools include the Model for End-Stage Liver Disease (MELD) score (values > 20 signify high short-term mortality), the Glasgow Alcoholic Hepatitis Score (GAHS), and the ABIC score (Age, serum Bilirubin, INR, serum Creatinine), each offering incremental prognostic information. Serial monitoring of the Lille score at Day 7 of steroid therapy (a value > 0.45 predicting non-response and mandating treatment discontinuation) is standard practice in all tertiary centers treating international patients.
The global standard of care for severe alcoholic hepatitis combines absolute alcohol cessation, intensive nutritional support (targeting 35–40 kcal/kg/day with 1.2–1.5 g/kg/day protein), corticosteroid therapy (prednisolone 40 mg/day for 28 days in responders), and vigilant management of complications including spontaneous bacterial peritonitis (SBP), hepatorenal syndrome (HRS), variceal hemorrhage, and hepatic encephalopathy. India's leading hepatology and liver transplant centers — including those affiliated with GAF Healthcare — offer multidisciplinary ACLF units combining hepatologists, critical care specialists, nephrologists, and transplant surgeons, providing internationally benchmarked outcomes at significantly lower cost than Western or Gulf-based counterparts.
Candidates
• ELIGIBLE PATIENTS:
• Adults with a confirmed diagnosis of alcoholic hepatitis based on clinical presentation (jaundice onset within 8 weeks, active or recent heavy alcohol use ≥ 80 g/day for > 5 years), elevated serum AST/ALT ratio > 2:1 with AST typically < 500 IU/L, elevated GGT, and raised total bilirubin
• Patients with severe AH (Maddrey DF ≥ 32, MELD > 18) requiring corticosteroid therapy, pentoxifylline rescue, or liver transplantation evaluation
• Patients with moderate AH (Maddrey DF 21–32) who have failed outpatient alcohol cessation and nutritional support
• Patients with complications requiring inpatient management: hepatic encephalopathy (West Haven Grade I–IV), hepatorenal syndrome (AKI-HRS), coagulopathy (INR > 1.5), refractory ascites, or esophageal varices
• Patients being evaluated for early liver transplantation (< 6 months sobriety protocols available at select India centers under strict ethics committee criteria)
• Family members or caregivers available to provide informed consent and social support (mandatory for transplant pathway)
• REQUIRED DIAGNOSTIC WORKUP BEFORE TREATMENT:
• Serum liver function tests (LFT): bilirubin (total/direct), ALT, AST, ALP, GGT, albumin
• Coagulation profile: PT, INR, aPTT
• Complete blood count (CBC) with differential
• Serum creatinine, urea, electrolytes (Na⁺, K⁺) — for MELD and HRS assessment
• Abdominal ultrasound with Doppler (portal hypertension, hepatic vein patency, ascites grading)
• FibroScan (transient elastography) for baseline fibrosis quantification where feasible
• Upper GI endoscopy (esophagogastric varices assessment and banding prophylaxis)
• Serum ferritin, transferrin saturation (exclude hemochromatosis)
• Viral hepatitis serology: HBsAg, Anti-HCV, Anti-HAV IgM, HEV IgM (critical to exclude co-existing viral hepatitis before initiating steroids)
• Blood cultures, urine culture, ascitic fluid analysis (SBP screen — SAAG, cell count, culture) prior to corticosteroid initiation
• Chest X-ray and ECG (pre-steroid baseline, transplant fitness)
• Liver biopsy via transjugular route (TJLB): considered gold standard for histological confirmation; essential when diagnosis is uncertain or before entering transplant evaluation pathway; avoids coagulopathy risk versus percutaneous approach
• Cross-sectional imaging (CT abdomen with contrast or MRI liver with hepatobiliary phase): to exclude hepatocellular carcinoma (HCC) and portal vein thrombosis in advanced disease
• Neuropsychological assessment (PHES, CFF) for covert hepatic encephalopathy if transplant pathway considered
• CONTRAINDICATIONS TO CORTICOSTEROID THERAPY (KEY TREATMENT COMPONENT):
• Active untreated bacterial, fungal, or viral infection (must be controlled before steroid initiation)
• Uncontrolled gastrointestinal bleeding within 48 hours
• Active or recent tuberculosis
• Uncontrolled diabetes mellitus (relative contraindication; requires intensive glucose monitoring)
• Renal failure unresponsive to volume resuscitation (pentoxifylline or N-acetylcysteine considered as alternatives)
• Lille score > 0.45 at Day 7 (mandates discontinuation of steroid course)
• CONTRAINDICATIONS TO LIVER TRANSPLANTATION EVALUATION:
• Inability to demonstrate alcohol abstinence commitment (no patient with < 6 months sobriety is considered at most India centers except under early transplant protocols with strict psychosocial screening)
• Active extrahepatic malignancy
• Severe cardiopulmonary disease precluding major surgery
• Ongoing multi-substance dependence without structured rehabilitation engagement
Procedure
TIER 1 — MEDICAL MANAGEMENT (FIRST-LINE FOR ALL PATIENTS)
Abstinence and Supportive Care: The single most important intervention is complete cessation of alcohol consumption. Medically supervised alcohol withdrawal management (CIWA-Ar protocol) with benzodiazepine titration (lorazepam or oxazepam preferred in liver disease due to safer metabolism) is initiated simultaneously with liver-directed therapy. Thiamine (100–200 mg IV) is administered immediately to prevent Wernicke-Korsakoff syndrome before any dextrose-containing fluids.
Nutritional Rehabilitation: Protein-calorie malnutrition is universal in severe AH and independently predicts mortality. High-calorie, high-protein enteral nutrition (EN) via nasogastric tube is preferred over parenteral nutrition (PN) whenever the gut is functional. Branched-chain amino acid (BCAA) supplementation (leucine, isoleucine, valine) reduces encephalopathy risk. Zinc, magnesium, phosphate, and B-vitamin repletion are standard. Indirect calorimetry-guided nutrition targets are used in ICU patients.
Corticosteroid Therapy (Severe AH, Maddrey DF ≥ 32):
• Prednisolone 40 mg/day orally for 28 days (IV methylprednisolone 32 mg/day if oral route impaired) remains the evidence-based backbone of severe AH therapy (STOPAH trial and subsequent meta-analyses confirm short-term survival benefit at 28 days).
• Lille Model Assessment at Day 7: A Lille score > 0.45 indicates non-response; steroids are discontinued to avoid infection risk without survival benefit. Complete response (Lille < 0.16) supports continuation for full 28-day course.
• Steroid use is avoided in patients with active infection; anti-fungal prophylaxis (fluconazole) and Pneumocystis pneumonia (PCP) prophylaxis (co-trimoxazole) are administered routinely during steroid courses at high-volume centers.
Pentoxifylline: A phosphodiesterase inhibitor with anti-TNF-α and anti-fibrotic properties, pentoxifylline 400 mg TID orally is used as an alternative or adjunct to corticosteroids, particularly when steroids are contraindicated. Its primary benefit is reduction of hepatorenal syndrome incidence (STOPAH trial data suggests limited additive benefit when used with steroids, but remains in clinical use for steroid-ineligible patients).
N-Acetylcysteine (NAC): Used adjunctively with prednisolone in severe AH to reduce oxidative stress, improve mitochondrial function, and potentially reduce infection risk. IV NAC protocols (150 mg/kg loading, then 12.5 mg/kg/hour infusion over 5 days) have shown improved 30-day survival in combination with steroids in select studies and are offered at advanced hepatology units in India and the UAE.
TIER 2 — MANAGEMENT OF COMPLICATIONS (PARALLEL TO MEDICAL THERAPY)
Hepatic Encephalopathy (HE): Lactulose (titrated to 2–3 soft stools/day) is first-line. Rifaximin 550 mg twice daily (non-absorbable antibiotic) is added for refractory or recurrent HE. Zinc supplementation supports urea cycle function. Covert HE is assessed with psychometric testing.
Hepatorenal Syndrome (HRS-AKI): Terlipressin (0.5–2 mg IV every 4–6 hours) combined with albumin infusion (1 g/kg on Day 1, then 20–40 g/day) is the gold standard for HRS-1 (now HRS-AKI per EASL 2018 guidelines). Norepinephrine plus albumin is an equivalent alternative in ICU settings. Renal replacement therapy (CRRT or intermittent hemodialysis) is instituted for refractory cases bridging to transplantation.
Variceal Hemorrhage: Urgent upper GI endoscopy with variceal band ligation (VBL) within 12 hours of bleeding onset. Pharmacological adjunct: terlipressin or octreotide infusion. Prophylactic non-selective beta-blockers (carvedilol 6.25–12.5 mg or propranolol) post-stabilization. TIPS (Transjugular Intrahepatic Portosystemic Shunt) placement considered for refractory bleeding or recurrent hemorrhage — available at select India and UAE centers.
Spontaneous Bacterial Peritonitis (SBP): Empiric IV third-generation cephalosporin (cefotaxime 2g every 8 hours or ceftriaxone 2g daily) initiated at diagnosis, with simultaneous albumin infusion (1.5 g/kg on Day 1, 1 g/kg on Day 3) to prevent HRS. Long-term norfloxacin 400 mg/day or rifaximin for secondary prophylaxis post-discharge.
TIER 3 — EARLY LIVER TRANSPLANTATION (SELECT SEVERE NON-RESPONDING PATIENTS)
Early liver transplantation (eLT) — defined as transplantation in patients with < 6 months of documented sobriety who have failed medical therapy — is offered at a limited number of specialized centers in India under stringent multi-disciplinary ethical and psychosocial selection protocols. Evidence from landmark trials (Mathurin et al., NEJM 2011; Thursz et al., Hepatology 2018) demonstrates that carefully selected early transplant candidates have 6-month survival rates exceeding 77% versus < 23% in non-transplanted non-responders. Patient selection criteria include: first episode of liver decompensation, strong social support, absence of other organ failure beyond the liver, no prior inpatient rehabilitation failure, and unanimous ethics committee approval.
Standard orthotopic liver transplantation (OLT) using deceased-donor or living-donor liver transplantation (LDLT) is performed. India is a global leader in LDLT, which offers shorter wait times than deceased-donor programs. Minimally invasive laparoscopic-assisted donor hepatectomy is available at premier India centers, reducing donor morbidity. Post-transplant immunosuppression protocols (tacrolimus-based CNI regimens + mycophenolate mofetil ± low-dose steroids) are standardized per international guidelines.
EMERGING & INVESTIGATIONAL THERAPIES (AVAILABLE AT LEADING CENTERS):
• Granulocyte-colony stimulating factor (G-CSF): 5 mcg/kg SC daily for 5 days, then every 3 days — promotes hepatic regeneration via mobilization of CD34⁺ bone marrow stem cells. Multiple RCTs from India (AIIMS, Global Hospital studies) have demonstrated improved 90-day survival and reduced MELD progression. Now incorporated into protocols at select Indian hepatology centers.
• Fecal Microbiota Transplantation (FMT): Targeting alcohol-related gut dysbiosis. Early-phase studies show improved encephalopathy outcomes and reduced infection; available in research protocols at Tier-1 India centers.
• IL-1β inhibitors (Anakinra): Under investigation for cytokine storm modulation in severe AH — not yet standard of care but available via compassionate use at select academic centers.
• Bovine colostrum and zinc-based gut-barrier therapies: Adjunctive investigational protocols for intestinal permeability reduction.
Cost of Alcoholic Hepatitis: India vs. UAE
The cost of alcoholic hepatitis treatment varies significantly based on disease severity (mild vs. severe vs. transplant-requiring), length of inpatient stay, ICU utilization, number of complications managed, and whether liver transplantation is part of the care pathway. India offers world-class hepatology and liver transplant care at 40–65% lower cost than comparable UAE institutions, while the UAE provides premium infrastructure, geographic accessibility from Europe and Africa, and luxury hospitality-grade medical facilities. Both destinations offer JCI-accredited centers with internationally trained hepatologists and transplant surgeons. The ranges below represent medical management costs only (non-transplant pathway); liver transplantation costs are quoted separately (LDLT in India: $25,000–$40,000; UAE: $60,000–$120,000+).
| Destination | Estimated Cost (USD) | Key Advantage |
|---|---|---|
| India | $3,000 – $12,000 | ~53% less than the UAE |
| UAE (Dubai/Abu Dhabi) | $7,000 – $25,000 | Premium care, JCI/DHA accredited |
Estimates typically include surgery, hospital stay, and standard medications. Contact us for a personalised quote.
Recovery & Aftercare
PHASE 1 — PRE-ARRIVAL & REMOTE CONSULTATION (Days -14 to 0)
• GAF Healthcare assigns a dedicated Case Manager within 24 hours of inquiry submission.
• Patient uploads all available records: LFTs, INR/PT, ultrasound/CT reports, prior hospitalization summaries, medication list, alcohol use history.
• GAF's partner hepatologist conducts a teleconsultation (video call) to calculate Maddrey DF, MELD, and ABIC scores from available data and establish urgency tier (urgent vs. elective).
• e-Medical Visa application is initiated for India-bound patients (typically 48–72-hour processing for urgent medical cases). UAE-bound patients from most nationalities receive visa-on-arrival or electronic travel authorization.
• Pre-admission blood tests and imaging may be advised locally to expedite hospital admission upon arrival.
• Dedicated airport reception (wheelchair-accessible) and direct transfer to the treating hospital arranged.
PHASE 2 — HOSPITAL ADMISSION & DIAGNOSTIC WORKUP (Days 1–3)
• Admission to hepatology unit or medical ICU (MICU/HDU) depending on MELD severity.
• Comprehensive baseline workup completed within 24 hours: LFTs, CBC, coagulation, renal panel, blood cultures, ascitic tap if ascites present, upper GI endoscopy, abdominal Doppler ultrasound, chest X-ray.
• Transjugular liver biopsy (TJLB) performed within 48 hours if histological confirmation required or transplant pathway evaluation initiated.
• Nutritional assessment by clinical dietitian; enteral nutrition via NGT initiated if oral intake inadequate (< 35 kcal/kg/day).
• Multidisciplinary team (MDT) meeting (hepatologist, intensivist, transplant surgeon, nephrologist, psychiatrist, dietitian) on Day 2–3 to formulate individualized treatment plan.
• Alcohol cessation monitoring initiated; psychiatry/addiction medicine consultation for withdrawal management and long-term sobriety planning.
PHASE 3 — ACUTE MEDICAL MANAGEMENT (Days 4–28)
• Prednisolone 40 mg/day initiated (if no active infection, GI bleed, or other contraindications confirmed by workup).
• Lille score calculated on Day 7: if > 0.45, steroids discontinued and pentoxifylline or NAC alternative protocol started.
• Daily clinical assessment: mental status (West Haven grading), abdominal girth, fluid balance, renal function trend.
• Complication management run concurrently: HRS treated with terlipressin + albumin; SBP with IV ceftriaxone + albumin; HE with lactulose + rifaximin; variceal bleed with endoscopic VBL + terlipressin.
• Weekly MELD and Lille reassessment; G-CSF adjunct therapy considered for MELD > 25 non-responders per institutional protocol.
• Transplant evaluation pathway (psychosocial assessment, ethics committee review, imaging for transplant suitability) runs in parallel if patient meets early transplant criteria.
PHASE 4 — STABILIZATION & STEP-DOWN (Days 14–28)
• Transition from MICU/HDU to hepatology ward as MELD stabilizes and complications resolve.
• Corticosteroid taper initiated after 28-day full course (5-day rapid taper to avoid adrenal suppression).
• Intensive nutritional rehabilitation continues; target oral caloric intake > 2,000 kcal/day with supervised meals.
• Structured alcohol rehabilitation program engagement (motivational interviewing, relapse prevention counseling) commenced during inpatient stay.
• Discharge planning initiated: Lille response documented, MELD at discharge recorded, outpatient hepatology follow-up schedule created.
• Medications prescribed for outpatient continuation: rifaximin, lactulose, propranolol/carvedilol (if varices), spironolactone/furosemide (if ascites), zinc, BCAA supplements, thiamine.
PHASE 5 — EARLY POST-DISCHARGE MONITORING IN COUNTRY (Weeks 4–8)
• Weekly outpatient hepatology clinic visits at the treating center (arranged by GAF Healthcare at affiliated clinics near patient accommodation).
• Serial LFTs, INR, creatinine, and bilirubin monitoring; MELD trend plotted weekly.
• Repeat upper GI endoscopy at Week 6–8 for variceal surveillance and re-banding if required.
• FibroScan (elastography) at Week 4 post-discharge as baseline for long-term fibrosis monitoring.
• GAF Case Manager conducts twice-weekly check-in calls during this period.
• Fit-to-fly assessment at Week 4 (moderate AH responders) or Week 6–8 (severe AH / complex course): physician clears for international flight when MELD < 15, no active HRS, no uncontrolled HE, INR < 1.8, and O2 saturation stable at altitude simulation (where applicable).
PHASE 6 — POST-RETURN FOLLOW-UP (Months 2–12)
• GAF Healthcare facilitates transfer of all medical records, histology reports, imaging, and discharge summaries to the patient's home country hepatologist.
• Teleconsultation with India/UAE treating physician at 1 month, 3 months, and 6 months post-return.
• MELD and Child-Pugh reassessment every 3 months; HCC surveillance (ultrasound + AFP) every 6 months if cirrhosis confirmed.
• Sobriety monitoring supported via alcohol rehabilitation liaison arranged by GAF's psychiatry partners.
Risks & Considerations
Alcoholic hepatitis carries inherent short-term mortality risk that is determined by disease severity at presentation rather than by the treating institution alone. Patients with severe disease (Maddrey DF ≥ 32) who do not respond to corticosteroids (Lille score > 0.45 at Day 7) face 28-day mortality rates of 25–40% even at expert centers — a biological reality that patients and families must understand before travel. Corticosteroid therapy itself carries significant risks in this population: immunosuppression predisposes to opportunistic infections (bacterial pneumonia, fungal infections including invasive aspergillosis, reactivation of latent tuberculosis — particularly relevant in India where TB prevalence is higher), hyperglycemia requiring insulin management, and gastrointestinal hemorrhage. Terlipressin used for hepatorenal syndrome can cause ischemic complications (bowel ischemia, limb ischemia, cardiac arrhythmia) and requires continuous cardiac monitoring. Liver transplantation, where applicable, carries surgical risks including primary non-function of the graft (1–5%), hepatic artery thrombosis (2–5%), biliary leak or stricture (10–15%), acute cellular rejection (20–30% but manageable with immunosuppression adjustment), and long-term immunosuppression-related complications including nephrotoxicity (tacrolimus), opportunistic infections, and de novo malignancy. G-CSF therapy may cause bone pain, splenomegaly, and rarely splenic rupture. Alcohol withdrawal during hospitalization carries its own risks (delirium tremens, seizures) requiring vigilant benzodiazepine-based management. Travel itself during acute illness represents risk; GAF Healthcare does not recommend international travel during active decompensation — stabilization at a local facility before transfer is always advised in acute presentations, and all travel clearance decisions rest with the treating physician.
Top Hospitals for Alcoholic Hepatitis
The following JCI and NABH-accredited hospitals are among the most experienced in specialist care, with dedicated teams and high-volume programmes.
Apollo Hospitals
New Delhi, India
Fortis Memorial Research Institute
Gurgaon, India
Medanta - The Medicity
Gurgaon, India
Max Super Specialty Hospital
New Delhi, India
Top Doctors for Alcoholic Hepatitis
Internationally trained specialists in Hepatology. Review their profiles, compare experience, and connect directly through GAF Healthcare.
Dr. Gopi Srikanth
MBBS, MD Internal Medicine, DM Gastroenterology and Hepatology, Fellowship in Pancreatology, Fellowship in Endoscopic Ultrasound
Gastroenterologist
Yashoda Hospitals, Hyderabad, India
10+ Yearsof experience
Dr. Gopi Srikanth is a Consultant Gastroenterologist and Hepatobiliary specialist at Yashoda Hospitals in Hyderabad, bringing over 10 years of clinical expertise in digestive and liver disease management. He holds a DM in Gastroenterology and Hepatology from AIIMS New Delhi and completed advanced fellowships in Pancreatology and Endoscopic Ultrasound from prestigious institutions including the World Endoscopy Organisation, which distinguish him as a… Read more
Dr. Guruprasad Shetty
MBBS, MS (General Surgery), DNB (General Surgery), FMAS, FIAGES, Fellowship in Surgical Gastroenterology and Minimally Invasive Surgery
Surgical Gastroenterologist & Hepatobiliary Surgeon
Apollo Hospitals, Mumbai, India
15+ Yearsof experience
Dr. Guruprasad Shetty is a Senior Consultant in Surgical Gastroenterology, Hepatopancreaticobiliary, and Transplant Surgery at Apollo Hospitals in Mumbai, bringing over 15 years of specialized surgical expertise. He holds exceptional credentials including MBBS, MS in General Surgery, DNB, FMAS (Fellowship in Minimal Access Surgery), and FIAGES, alongside a specialized fellowship in Surgical Gastroenterology and Minimally Invasive Surgery. His… Read more
Dr. Hitesh Panchal
MBBS, MD in Internal Medicine, DrNB in Gastroenterology
Gastroenterologist
Medanta - The Medicity, Gurgaon, India
9+ Yearsof experience
Dr. Hitesh Panchal is an Associate Consultant in Gastroenterology & Hepatobiliary Medicine at Medanta – The Medicity in Gurgaon, bringing 9+ years of clinical experience to the care of complex digestive and liver disorders. He completed his medical training at the esteemed B.J. Medical College, Ahmedabad, earning his MBBS in 2017 and MD in Internal Medicine in 2020, before pursuing his DrNB in Gastroenterology at Medanta, one of India's leading… Read more
Dr. Imtiakum Jamir
MBBS, MS, MCh
Hepato-Pancreato-Biliary Surgeon & Liver Transplant Specialist
BLK-Max Super Speciality Hospital, New Delhi, India
8+ Yearsof experience
Dr. Imtiakum Jamir is a Principal Consultant in Hepato-Pancreato-Biliary (HPB) Surgery and Liver Transplantation at the Institute for Digestive & Liver Diseases, BLK-Max Super Speciality Hospital in New Delhi. With more than 8 years of dedicated clinical experience, he has established himself as a leading specialist in complex liver, pancreatic, and biliary surgical disorders. His training foundation includes a postgraduate degree (MCh) in HPB Surgery,… Read more
Dr. Inbaraj Balradja
MBBS, MS (General Surgery), M.Ch. (General Surgery)
Hepatobiliary & Liver Transplant Surgeon
Fortis Hospital, Shalimar Bagh, New Delhi, India
9+ Yearsof experience
Dr. Inbaraj Balradja is a Senior Consultant in Liver Transplant Surgery and Hepatobiliary Surgery at Fortis Hospital, Shalimar Bagh, New Delhi. With over 9 years of dedicated experience in hepato-pancreato-biliary (HPB) surgery and transplantation, he has become a trusted expert in both adult and pediatric liver transplantation. Dr. Balradja completed his foundational training at the prestigious All India Institute of Medical Sciences (AIIMS), New Delhi,… Read more
Frequently Asked Questions — Alcoholic Hepatitis
The cost of alcoholic hepatitis medical management depends heavily on disease severity, ICU requirements, duration of inpatient stay, number of complications requiring intervention, and whether liver transplantation is part of the pathway. For non-transplant medical management (corticosteroid therapy, nutritional rehabilitation, complication management such as HRS, SBP, and hepatic encephalopathy), the estimated costs are as follows: In India (NABH/JCI-accredited centers), expect USD $3,000–$12,000 for a full course of inpatient treatment, inclusive of hospital stay (14–28 days), specialist hepatologist fees, medications (prednisolone, terlipressin, albumin infusions, rifaximin), nursing care, standard diagnostic workup (LFTs, INR, ultrasound Doppler, upper GI endoscopy), and ICU or HDU charges where applicable. In the UAE (JCI- and DHA-accredited hospitals in Dubai or Abu Dhabi), equivalent treatment is estimated at USD $7,000–$25,000, reflecting premium infrastructure, higher nursing-to-patient ratios, and luxury inpatient accommodation. For patients requiring liver transplantation (living-donor liver transplantation — LDLT), costs in India range from USD $25,000–$40,000 inclusive of surgery, immunosuppression induction, and 30-day post-operative care; in the UAE, LDLT ranges from USD $60,000–$120,000+. GAF Healthcare provides a transparent itemized cost estimate before any commitment to travel, based on individual patient records reviewed by partner hepatologists. All estimates are for guidance; final costs depend on individual clinical course.
The minimum in-country stay before international air travel is safe depends entirely on your clinical trajectory, disease severity, and whether complications arose during treatment. For moderate alcoholic hepatitis (Maddrey DF < 32) with good corticosteroid response (Lille score < 0.16 at Day 7) and no significant complications, inpatient stay is typically 14–21 days, followed by 1–2 weeks of outpatient monitoring, making a total in-country stay of approximately 4–5 weeks before fit-to-fly clearance. For severe alcoholic hepatitis (Maddrey DF ≥ 32) with complications such as hepatorenal syndrome, hepatic encephalopathy, variceal hemorrhage, or SBP, inpatient stay extends to 21–28+ days, and post-discharge outpatient monitoring is essential for 2–4 additional weeks, making total in-country stay 6–8 weeks before fit-to-fly assessment. Fit-to-fly clearance is issued by the treating hepatologist when all of the following are met: MELD score < 15 or demonstrably stable, no active hepatic encephalopathy, INR < 1.8, no active infection, renal function stable, and oxygen saturation adequate for altitude-equivalent conditions. Air travel in patients with severe hepatic disease carries risks of worsening encephalopathy due to relative hypoxia and deep vein thrombosis due to prolonged immobility; low-molecular-weight heparin (LMWH) prophylaxis and business-class seating (for lie-flat capability) are advised for long-haul flights. Patients who enter the liver transplantation pathway will require a minimum 6–8 week post-transplant stay and are typically fit to fly at 8–12 weeks post-operatively. GAF Healthcare arranges all follow-up outpatient appointments during the post-discharge monitoring period and coordinates fit-to-fly documentation with the treating physician.
Success rates for alcoholic hepatitis treatment must be interpreted in the context of disease severity at presentation, as this is the dominant determinant of outcomes. For moderate alcoholic hepatitis (Maddrey DF < 32, MELD < 18): 28-day survival with optimized medical management (nutritional support, abstinence, supportive care) exceeds 90%, and 6-month survival approaches 85–90% in patients who maintain alcohol abstinence. For severe alcoholic hepatitis (Maddrey DF ≥ 32, MELD > 20) treated with prednisolone at high-volume hepatology centers: 28-day survival is approximately 75–80% in corticosteroid responders (Lille score ≤ 0.45 at Day 7). Non-responders (Lille > 0.45) face significantly higher short-term mortality (approximately 25–40% at 28 days with medical management alone), and early liver transplantation evaluation is initiated for eligible candidates in this subgroup. For patients who receive early liver transplantation (selected severe non-responders): 1-year post-transplant survival exceeds 75–80% at specialized Indian LDLT centers, consistent with international transplant registry outcomes. India's premier liver transplant institutions — several of which are GAF Healthcare partners — report LDLT outcomes comparable to or exceeding those of many Western transplant programs, with high case volumes (> 200 LDLT procedures/year at leading centers) contributing to superior surgical proficiency. Long-term success is critically dependent on sustained alcohol abstinence: relapse rates of 10–25% at 2 years post-treatment significantly impact fibrosis progression and long-term survival, which is why GAF Healthcare coordinates structured addiction medicine and psychiatric follow-up as part of every patient's care plan.
Why Plan Your Treatment Through Gaf Healthcare?
GAF Healthcare provides comprehensive end-to-end non-medical support designed specifically for international patients traveling to India or the UAE for complex hepatological care.
INDIA-BOUND PATIENTS:
• e-Medical Visa Assistance: GAF's visa team prepares and submits all documentation for the Indian e-Medical Visa (eM-Visa), which allows the patient plus up to two attendants (on e-MedAttendant Visa). Visa processing typically takes 48–72 hours for most nationalities under urgent medical grounds. We provide the hospital invitation letter, treatment confirmation, and all supporting documentation required by the Indian consulate or VFS Global portal.
• Airport Reception: Dedicated ground team meets patients at all major international airports (Indira Gandhi International Delhi, Chhatrapati Shivaji International Mumbai, Kempegowda International Bengaluru, Chennai International) with name-board, wheelchair assistance, and direct ambulance or executive transfer to the treating hospital.
• Language Support: Certified medical interpreters available in Arabic, Russian, French, Swahili, Bangla, Dari, and Nepali accompany patients during all clinical consultations, ward rounds, and consent discussions.
• Attendant Accommodation: GAF coordinates serviced apartments, guest houses within hospital campuses, or partnered hotels within 2 km of the treating hospital, ranging from budget to 5-star, with 24-hour concierge support for attendant family members.
• SIM Card, Currency Exchange & Local Transport: Pre-arranged local SIM with data, currency exchange advisory, and dedicated driver for outpatient clinic visits during the post-discharge monitoring phase.
UAE-BOUND PATIENTS (DUBAI / ABU DHABI):
• Visa Facilitation: Citizens of 50+ nationalities receive visa-on-arrival or free visa to the UAE. For nationalities requiring advance visas, GAF coordinates hospital-sponsored medical visa applications via the DHA (Dubai Health Authority) or DOH (Abu Dhabi Department of Health) medical visa pathways. Typical processing: 3–7 working days.
• Hospital Partnerships: GAF works with JCI-accredited, DHA-licensed hospitals in Dubai Healthcare City (DHCC) and Abu Dhabi — offering single-room inpatient suites, multi-lingual nursing staff, and internationally trained hepatology and transplant teams.
• Airport Transfers: Business-class ground transfer from Dubai International (DXB), Al Maktoum International (DWC), or Abu Dhabi International (AUH) to treating hospital.
• Accommodation: Partnered hotels within DHCC or adjacent to Abu Dhabi's medical districts, including accessible rooms for attendants with dietary catering available.
• Concierge Medical Support: GAF's UAE coordinator liaises with the treating team daily, provides written clinical updates translated into the patient's language, and manages appointment scheduling throughout the treatment stay.
COMMON TO BOTH DESTINATIONS:
• Second Opinion Facilitation: Before travel, GAF arranges a pre-travel teleconsultation with the target hospital's hepatologist to confirm treatment plan suitability and avoid unnecessary travel in non-eligible patients.
• Insurance Liaison: GAF assists in communicating with international health insurers for pre-authorization documentation.
• Emergency Repatriation Planning: For patients at risk of acute deterioration, GAF coordinates with air ambulance providers and maintains 24/7 emergency helpline access for attendant families.
Patients Also Explore
Other treatments commonly sought by patients considering Alcoholic Hepatitis.
Liver Transplant
Transplant
Lung Transplant
Transplant
Colonoscopy & Polypectomy
Gastroenterology
Hepatitis B Treatment
Gastroenterology